|
|
|
| Effect of Naoxueshu Oral Liquid on Hematoma Absorption and Neuroinflammation in Patients with Residual Hematoma during Recovery after Intracerebral Hemorrhage |
| HAO Yingying, SONG Xiaozheng, LIU Jinhui, et al |
| Department of General Medicine, Zhumadian First People's Hospital, Zhumadian Henan 463000 |
|
|
|
|
Abstract 【Objective】 To investigate the effects of Naoxueshu Oral Liquid on hematoma absorption and neuroinflammation in patients with residual hematoma during the recovery stage of spontaneous intracerebral hemorrhage (ICH).【Methods】 A total of 78 patients with residual hematoma during ICH recovery were randomly divided into a control group and an observation group, with 39 cases in each. Both groups received standardized ICH treatment, while the observation group was additionally treated with Naoxueshu Oral Liquid. Hematoma absorption, absolute and relative perilesional edema (PHE) volume, edema resolution time, neutrophil-to-lymphocyte ratio (NLR), systemic inflammation response index (SIRI), tumor necrosis factor-α (TNF-α), malondialdehyde (MDA), superoxide dismutase (SOD), and reduced glutathione (GSH) levels were compared between the two groups before and after 30 days of treatment.【Results】After 30 days of treatment, hematoma volume was significantly reduced in both groups (P<0.05), with the observation group showing smaller hematoma volume, higher absorption rate, and shorter complete absorption time than the control group (all P<0.05). PHE volume decreased in both groups (P<0.05), however, the observation group had lower absolute and relative PHE volume and shorter edema resolution time than the control group (all P<0.05). After treatment, NLR, SIRI, and TNF-α levels decreased compared with pretreatment values (P<0.05), and their levels in the observation group were lower than those in the control group (P<0.05). MDA level decreased, while both SOD and GSH levels increased in both groups after treatment (all P<0.05); while the observation group exhibited lower MDA and higher levels of SOD and GSH compared to the control group (P<0.05).【Conclusion】 Naoxueshu Oral Liquid, when combined with conventional rehabilitation therapy, can significantly promote hematoma and perilesional edema absorption, alleviate neuroinflammatory responses, and improve oxidative stress status in patients during the recovery phase of ICH.
|
|
Received: 10 July 2025
|
|
|
|
|
|
[1] ZHENG X C,GAO J L,ZHAO M M,et al.Honokiol attenuates mitochondrial fission and cell apoptosis by activating Sirt3 in intracerebral hemorrhage[J].Chin Med J (Engl),2023,136(6):719-731.
[2] 杨新悦,刘书含,王少君.脑出血复发的危险因素[J].国际脑血管病杂志,2025,33(1):52-58.
[3] 魏文渊,别小华,韩超.影响高血压脑出血患者微创置管引流术后血肿未完全清除的相关因素[J].医学临床研究,2023,40(4):481-484.
[4] 王新志,高颖,周红霞,等.脑血疏口服液治疗中风临床应用专家共识[J].中华中医药学刊,2024,42(8):249-258.
[5] DENG P P, WU N, CHEN X J,et al.NIHSS–the alberta stroke program early CT Score mismatchin guiding thrombolysis in patients with acute ischemic stroke[J].J Neurol,2022,269(3):1515-1521.
[6] 邓里娜,吴波.《中国脑出血诊治指南2019》更新要点及解读[J].心脑血管病防治,2021,21(1):13-17.
[7] 宗达,丁大冬,曹纹平.内镜辅助下长轴入路血肿清除术治疗中等量幕上自发性脑出血的临床研究[J].中国现代医学杂志,2024,34(6):80-85.
[8] 任小倩,崔莹莹,金小煜.改良CT图像评分评估脑出血患者预后的临床价值[J].医学临床研究,2025,42(2):336-338.
[9] 侯建辉,李强.靶向Nrf2-铁死亡通路抑制脑出血后继发性脑损伤研究进展[J].河北医科大学学报,2024,45(9):1037-1040.
[10] 齐洪武,刘岩松,曾维俊,等.脑血疏口服液佐治高血压脑出血临床评价[J].中国药业,2025,34(8):94-98.
[11] 于苗,张丽娜,丁薇,等.血肿微创清除联合脑血疏口服液治疗自发性脑出血的疗效及安全性的Meta分析与质量评价[J].海南医学院学报,2024,30(9):691-699.
[12] 宋歌亮,季昭臣,陈哲,等.脑血疏口服液治疗出血性脑卒中有效性与安全性的Meta分析[J].中国医院用药评价与分析,2023,23(6):719-722.
[13] 商健,赵哲,王新志.脑血疏口服液治疗缺血性脑卒中的Meta分析及试验序贯分析[J].中西医结合心脑血管病杂志,2022,20(24):4469-4477.
[14] 惠红岩,周芳,周祥.基于网络药理学和分子对接技术探讨脑血疏口服液治疗缺血性卒中的作用机制[J].海南医学,2023,34(21):3049-3055. |
|
|
|
2025, Vol. 42 
